DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is based on the finding that a compound having poor water solubility (weakly basic, neutral and / or nonionic, or weakly acidic compound), water soluble polymer (s), pH sensitive polymer (s) (enteric polymer, Or gastric soluble polymers which are soluble in gastric juices such as Eudragit E and insoluble in the intestinal pH range) and / or improves the solubility / dissolution of this compound in aqueous media at both low and neutral pH To a novel solid dispersion pharmaceutical composition for the preparation of a composition comprising a pharmaceutically acceptable surfactant which provides a relatively pH independent dissolution profile.Selection drawing None本発明は、難水溶性を有する化合物(弱塩基性、中性および/もしくは非イオン性、または弱酸性化合物)、水溶性ポリマー(複数可)、pH感受性ポリマー(複数可)(腸溶性ポリマー、またはEudragit Eなどの胃液では可溶性で腸のpH範囲では不溶性である胃溶性ポリマーのいずれか)、ならびに/または低pHおよび中性pHの両方の水性媒体中のこの化合物の溶解度/溶解を改善して相対的にpH非依存性の溶解プロファイルを提供する医薬的に許容し得る界面活性剤から成る組成物の調製のための新規な固体分散体医薬組成物に関する。【選択図】なし
